Molecule One sp. z o.o.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Molecule One sp. z o.o. - overview
Established
2016
Location
Warszawa, -, Poland
Primary Industry
Pharmaceuticals
About
Molecule One sp. z o. o. provides advanced chemical synthesis services, specializing in drug discovery solutions through its proprietary SpaceM1 platform, enabling rapid access to diverse compounds for pharmaceutical research.
Founded in 2016, Molecule One sp. z o. o. operates out of Warszawa, Poland.
The company focuses on high-quality chemical synthesis services and has undergone recent growth, highlighted by its Seed funding round in June 2021, raising USD 4. 6 mn led by ATMOS Ventures, with contributions from multiple investors. Piotr Byrski, a co-founder and current CEO, is instrumental in driving the company’s strategic vision. Molecule.
one specializes in high-quality chemical synthesis services, offering direct-to-biology plates with a variety of compounds from their proprietary SpaceM1 platform. Utilizing advanced generative models and leveraging a dataset of over 100,000 reactions from their high-throughput experimentation lab established in 2021, they streamline drug discovery processes. Clients, including pharmaceutical companies and research institutions across North America, Europe, and Asia, can access over 1 trillion de novo drug-like molecules for rapid synthesis within 2-6 weeks. The company is also developing Maria, an AI-driven agent aimed at automating molecular synthesis, enhancing efficiency and precision.
In 2023, Molecule One sp. z o. o. reported a revenue of USD 348,325.
2 with an EBITDA of USD 142,115. 8. Revenue generation is primarily through B2B partnerships with pharmaceutical and biotech firms, structured around project-based contracts and success-fee agreements, emphasizing customized synthesis services powered by their SpaceM1 technology. Following its Seed funding round in June 2021, where Molecule One sp.
z o. o. raised USD 4. 6 mn, the company plans to utilize these funds to expand its team and initiate growth strategies.
Upcoming initiatives include opening new offices in the U. S. and Western Europe by 2025, along with the development of new products to enhance their service offerings in chemical synthesis.
Current Investors
Sunfish Partners, AME Cloud Ventures, Cherubic Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.molecule.one
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Molecule One sp. z o.o. - timeline of key events
Molecule One sp. z o.o. - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | 43,276.7 | 555,282.3 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | 1183.1% | - | - | - |
| EBITDA (USD) | (5,845.2) | - | (842,610.7) | (547,097.3) | - | - | - |
| Operating Income (USD) | (5,845.2) | - | (862,410.7) | (547,097.3) | - | - | - |
| Operating Margin | - | - | (1992.8%) | (98.5%) | - | - | - |
| % EBITDA Margin | - | - | (1947.0%) | (98.5%) | - | - | - |
| NET Income (USD) | (5,943.5) | (19,188.4) | (862,410.7) | (530,193.7) | - | - | - |
| % Net Margin | - | - | (1992.8%) | (95.5%) | - | - | - |
Molecule One sp. z o.o. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.